SCHEMBL7843423

SCHEMBL7843423

CCN1C=CC=CC1N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL27874294 0.98
SCHEMBL3777009 0.82
SCHEMBL27918945 0.79
SCHEMBL17734086 0.78
SCHEMBL13021206 0.73
SCHEMBL27729359 0.71
Bromide SCHEMBL28337037 0.71
SCHEMBL7747951 0.71
SCHEMBL27537074 0.71
SCHEMBL9644704 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101781305-A Method for artificially synthesizing galanthamine TAIZHOU JINZHAO WEIYE FINE CHE 2010-07-21 CN claimed
WO-2022208382-A1 NOVEL DIALKOXYNAPHTHO[2,3-C]FURAN-1(3H)-ONE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESPIRATORY DISEASE OR SARS-COV-2 INFECTION DISEASE, COMPRISING SAME 동화약품주식회사 2022-10-06 WO disclosed
CN-101781305-A Method for artificially synthesizing galanthamine TAIZHOU JINZHAO WEIYE FINE CHE 2010-07-21 CN disclosed
EP-0819108-B1 Process for preparing galanthamine derivatives by asymmetric reduction JANSSEN PHARMACEUTICA NV (BE) 2001-08-29 EP disclosed
US-6018043-A Process for preparing galanthamine derivatives by asymmetric reduction JANSSEN PHARMACEUTICA, N.V. (BE) 2000-01-25 US disclosed
EP-0819108-A1 PROCESS FOR PREPARING GALANTHAMINE DERIVATIVES BY ASYMMETRIC REDUCTION Chiroscience Limited (GB) 1998-01-21 EP disclosed
WO-1996031453-A1 PROCESS FOR PREPARING GALANTHAMINE DERIVATIVES BY ASYMMETRIC REDUCTION CHIROSCIENCE LIMITED (GB) 1996-10-10 WO disclosed